Company intelligence / Profile preview

Aurospharma

San Diego, California, USA

Ownership: Private
Development stage: Other

Overview

Auros Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare metabolic diseases, particularly Urea Cycle Disorders (UCD). The company's lead program, ARS-101, is a next-generation nitrogen scavenger designed to provide a more effective and patient-friendly alternative to existing treatments for hyperammonemia. By leveraging advanced drug delivery and formulation technologies, Auros Pharma aims to address the significant unmet needs of patients living with life-threatening orphan conditions. The company is privately held and based in San Diego, California.

Therapeutic areas: Metabolic Disorders
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

AU1002

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Aurospharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aurospharma.

Explore the full profile